Drug Trial Radar · NCT07686068
First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Jul 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
260
Planned (sponsor's estimate)
Start
Aug 18, 2026
Primary completion
Dec 1, 2028
Study completion Dec 1, 2028
Sponsor
- Lead sponsor
- VelaVigo Bio IncIndustry
- Sponsor type
- Industry
- First posted
- Jul 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC106.
Conditions
- Participants With Advanced Solid Tumor Malignancies
Interventions
VBC106Drug
VBC106
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose-limiting toxicities (DLT) as defined in the protocolTime frame: (DLT)From time of first dose of VBC106 to end of DLT period (approximately 21 days)
- Incidence of Serious Adverse EventsTime frame: From time of Informed Consent to 30 days post last dose of VBC106
- Incidence of Adverse Events (AEs)Time frame: From time of Informed Consent to 30 days post last dose of VBC106
Locations
4 sites in 2 countries. Site status is shown where the registry gives one.
NEXT Oncology Houston
Houston, Texas
START Mountain Region, LLC.
West Valley City, Utah
NEXT Oncology Virginia
Fairfax, Virginia
Icon Cancer Centre Wesley
Brisbane, Queensland, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.